<DOC>
	<DOCNO>NCT01759602</DOCNO>
	<brief_summary>The overall objective evaluate tolerability/safety preliminary efficacy CINRYZEÂ® ( C1 esterase inhibitor [ human ] ) add-on therapy treatment acute optic neuritis and/or transverse myelitis NMO NMOSD . Primary Objective : To evaluate safety tolerability 3-5 dos 1000 - 2000 Units intravenous CINRYZE NMO/NMOSD patient acute exacerbation . Secondary Objectives : - To determine frequency adverse event CINRYZE patient population . - To determine effect CINRYZE NMO clinical score ( Expanded Disability Status Scale Low Contrast Visual Acuity ) . - To compare change MRI lesion size extent follow course CINRYZE .</brief_summary>
	<brief_title>C1-esterase Inhibitor ( Cinryze ) Acute Treatment Neuromyelitis Optica Exacerbation</brief_title>
	<detailed_description>The rationale use C1-esterase inhibitor ( CINRYZE ) NMO base pathology show role complement active NMO lesion . NMO unique involve complement , may pathogenic role demyelinate disease include multiple sclerosis . However , NMO characterize complement involvement deposit rim rosette pattern all/most active lesion . In vitro , complement mediates damage initiate anti-AQP4 antibody bind astrocyte . The effector antibody trigger cell damage complement cascade block complement cascade C1-inhibitor prevents damage ex vivo . Based mount evidence , consensus field prevention complement cascade CNS would ameliorate damage cause NMO inflammatory attack . In contrast prevention trial , study would provide complement inhibition active NMO attack . This approach design administer inhibitory drug complement damage peak minimize adverse effect prolong complement inhibition . Patients NMO lack natural C1-esterase inhibitor , artificially tip balance suppress complement pathway use purified human C1-esterase inhibitor patient hyperactive complement activation show beneficial myocardial infarction sepsis . Similarly , rationale add human C1-esterase inhibitor treatment NMO acute exacerbation tip balance toward complement suppression effort reduce complement-mediated neurologic damage . This phase 1b open-label , interventional proof-of-concept study subject receive 3 daily infusion 2000 Units intravenous CINRYZE onset NMO exacerbation , plus additional 2 infusion 1000 Units intravenous CINRYZE second treatment phase plasma exchange , necessary .</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>1 . Able willing provide write informed consent . 2 . 1865 year age . 3 . New acute optic neuritis and/or transverse myelitis . A clinical event define episode inflammation spinal cord and/or optic nerve lead neurologic symptom ascribe another disease process . 4 . Diagnosis NMO accord 2006 revision Wingerchuk diagnostic criterion NMO ( Wingerchuk , 2006 ) , AQP4 positive NMOSD per EFNS Guidelines . For NMO , subject must two absolute criterion : 1. optic neuritis 2. myelitis least two three supportive criterion : 3. presence contiguous spinal cord MRI lesion extend three vertebral segment , 4 . MRI criterion NOT satisfy revise McDonald diagnostic criterion MS [ Polman , 2011 ] 5 . NMOIgG ( AQP4 ) serum . For NMOSD , subject must longitudinally extensive transverse myelitis ( LETM ) recurrent isolate optic neuritis ( RION ) /bilateral optic neuritis ( BON ) , opticospinal multiple sclerosis ( OSMS ) AQP4 antibody positive . 5 . A female subject eligible enter study : A . Not pregnant nursing ; B . Of nonchildbearing potential ( i.e . woman hysterectomy , postmenopausal , define &gt; 2 year without menses , female subject postmenopausal &lt; 2 year , must confirm Follicle Stimulating Hormone ( FSH ) estradiol level ) , ovaries surgically remove current document tubal ligation ) OR Of childbearing potential ( i.e . woman functional ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhoea ( even severe ) , woman perimenopausal begin menstruate . C. Subject negative serum pregnancy test screen agree one following : 1 . Complete abstinence intercourse period consent study 6 month last dose investigational product ; , 2 . Consistent correct use one follow acceptable method birth control period consent study 6 month last dose investigational product : . Oral contraceptive ( either combine progesterone ) ii . Injectable progesterone iii . Levonorgestrel implant iv . Estrogenic vaginal ring v. Percutaneous contraceptive patch vi . Intrauterine device ( IUD ) intrauterine system ( IUS ) document failurerate &lt; 1 % per year vii . Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study ; male must sole partner subject viii . Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . 1 . Current evidence know history clinically significant infection include : 1 . Chronic ongoing active infectious disease require long term systemic treatment , limited : PML , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis , active hepatitis C. 2 . Previous serious opportunistic atypical infection . 3 . History positive serology hepatitis B . 4 . Prior history , suspicion , tuberculosis ( TB ) 5 . History positive serology HIV . 2 . History clinically significant CNS trauma ( e.g . traumatic brain injury , cerebral contusion , spinal cord compression ) . 3 . History presence myelopathy due spinal cord compression disc vertebral disease . 4 . Past current history medically significant adverse effect ( include allergic reaction ) : a. Corticosteroids 5 . Past current malignancy , except 1 . Cervical carcinoma Stage 1B less 2 . Noninvasive basal cell squamous cell skin carcinoma 3 . Cancer diagnose duration complete response ( remission ) &gt; 5 year 4 . A history hematologic malignancy excludes subject participation , regardless response . 6 . Significant concurrent , uncontrolled medical condition include , limited , cardiac , renal , hepatic , hematological , gastrointestinal , endocrine , immunodeficiency syndrome , pulmonary , cerebral , psychiatric , neurological disease could affect subject 's safety , impair subject 's reliable participation trial , impair evaluation endpoint , necessitate use medication allow protocol , determine PI study . 7 . Use investigational drug experimental therapy condition NMO within 4 week , 5 pharmacokinetic half live duration biological effect ( whichever longer ) prior screen . 8 . Current participation interventional clinical trial . Participation noninterventional trial require approval protocol investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Neuromyelitis optica</keyword>
	<keyword>Devic 's disease</keyword>
	<keyword>NMO</keyword>
	<keyword>Devic</keyword>
</DOC>